ArticlePloS one2025
Common molecular links and therapeutic insights between type 2 diabetes and kidney cancer.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Construction and validation of a prognostic model associated with chromatin remodeling in hepatocellular carcinoma.Translational cancer research · 2026Article
- Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis.Frontiers in endocrinology · 2026Article
- Identification and preliminary clinical validation of type 2 diabetes signature genes through machine learning analysis of scRNA-seq data.Frontiers in medicine · 2026Article
- LST1: a novel biomarker for efferocytosis in the co-occurrence of type 2 diabetes mellitus and clear cell renal cell carcinoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes (T2D) is considered as a risk factor for kidney cancer (KC). However, so far, there is no study in the literature that has explored genetic factors through which T2D drive the development and progression of KC. Therefore, this study attempted to explore T2D- and KC-causing shared key genes (sKGs) for revealing shared pathogenesis and therapeutic drugs as their common treatments.
methodsThe integrated bioinformatics and system biology approaches were utilized in this study. The statistical LIMMA approach was used based web-tool GEO2R to detect differentially expressed genes (DEGs) through transcriptomics analysis. Then upregulated and downregulated DEGs for T2D and KC were combined to obtained shared DEGs (sDEGs) between T2D and KC. The STRING database was used to construct the protein-protein interaction (PPI) network of sDEGs. Then Cytohubba plugin-in Cytoscape were used in the PPI network to disclose the sKGs based on different topological measures. The RegNetwork database was used in NetworkAnalyst to analyze co-regulatory networks of sKGs with transcription factors (TFs) and micro-RNAs to identify key TFs and miRNAs as the transcriptional and post-transcriptional regulators of sKGs, respectively. AutoDock Vina is a tool used for molecular docking. ADME/T properties were 24 assessed using pkCSM and SwissADME.
resultsAt first, 74 shared DEGs (sDEGs) were identified that can distinguish both KC and T2D patients from control samples. Through protein-protein interaction (PPI) network analysis, top-ranked 6 sDEGs (CD74, TFRC, CREB1, MCL1, SCARB1 and JUN) were detected as the sKGs that drive both KC and T2D development and progression. The most common sKG 'CD74' is associated with key pathways, such as NF-κB signaling transduction, apoptotic processes, B cell proliferation. Differential expression patterns of sKGs validated by independent datasets of NCBI database for T2D and TCGA and GTEx databases for KC. Furthermore, sKGs were found to be significant at several CpG sites in DNA methylation studies. Regulatory network analysis identified three TFs proteins (SMAD5, ATF1 and NR2F1) and two miRNAs (hsa-mir-1-3p and hsa-mir-34a-5p) as the regulators of sKGs. The enrichment analysis of sKGs with KEGG-pathways and Gene Ontology (GO) terms revealed some crucial shared pathogenetic mechanisms (sPM) between two diseases. Finally, sKGs-guided four potential therapeutic drug molecules (Imatinib, Pazopanib hydrochloride, Sorafenib and Glibenclamide) were recommended as the common therapies for KC with T2D.
conclusionThe results of this study may be useful resources for the diagnosis and therapy of KC with the co-existence of T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.